Artículos por temáticas
En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.
Tema
2011
4001 ARTíCULOS , VIENDO DEL 1 AL 15
Impulsive behavior and associated clinical variables in Parkinson's disease.
Abosch A, Gupte A, Eberly LE, Tuite PJ, Nance M, Grant JE.
Psychosomatics. 2011 Jan-Feb;52(1):41-7. doi: 10.1016/j.psym.2010.11.013.
0
0
0
Müller-Vahl KR, Roessner V; European Society for the Study of Tourette Syndrome..
Mov Disord. 2011 Nov;26(13):2447; author reply 2448. doi: 10.1002/mds.23958. No abstract available.
0
0
0
Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest.
Falcone DC, Wood EM, Xie SX, Siderowf A, Van Deerlin VM.
J Genet Couns. 2011 Aug;20(4):384-95. doi: 10.1007/s10897-011-9362-0.
0
0
0
Attention to self in psychogenic tremor.
van Poppelen D, Saifee TA, Schwingenschuh P, Katschnig P, Bhatia KP, Tijssen MA, Edwards MJ.
Mov Disord. 2011 Dec;26(14):2575-6. doi: 10.1002/mds.23911. No abstract available.
0
0
0
Vocal acoustic characteristics of patients with Parkinson's disease.
Tanaka Y, Nishio M, Niimi S.
Folia Phoniatr Logop. 2011;63(5):223-30. doi: 10.1159/000322059.
0
0
0
Neurobehavioral mechanisms of temporal processing deficits in Parkinson's disease.
Harrington DL, Castillo GN, Greenberg PA, Song DD, Lessig S, Lee RR, Rao SM.
PLoS One. 2011 Feb 25;6(2):e17461. doi: 10.1371/journal.pone.0017461.
0
0
0
The opsoclonus–myoclonus syndrome.
Sahu JK, Prasad K.
Pract Neurol. 2011 Jun;11(3):160-6. doi: 10.1136/practneurol-2011-000017.
0
0
0
Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease.
Maraganore DM.
J Mov Disord. 2011 May;4(1):1-7. doi: 10.14802/jmd.11001. Review.
0
0
0
Swarup V, Srivastava AK, Padma MV, Rajeswari MR.
DNA Cell Biol. 2011 Jun;30(6):389-94. doi: 10.1089/dna.2010.1165.
0
0
0
Contrafatto D, Mostile G, Nicoletti A, Raciti L, Luca A, Dibilio V, Lanzafame S, Distefano A, Drago F, Zappia M.
Clin Neuropharmacol. 2011 Mar-Apr;34(2):71-3. doi: 10.1097/WNF.0b013e318211f945.
0
0
0
Cell therapy for Parkinson's disease: have the glory days gone?
Albanese A.
Lancet Neurol. 2011 Jun;10(6):492-3. doi: 10.1016/S1474-4422(11)70101-6. No abstract available.
0
0
0
Desserre J, Devos D, Sautière BG, Debruyne P, Santorelli FM, Vuillaume I, Defoort-Dhellemmes S.
Cerebellum. 2011 Dec;10(4):758-62. doi: 10.1007/s12311-011-0286-x.
0
0
0
Bladder, bowel, and sexual dysfunction in Parkinson's disease.
Sakakibara R, Kishi M, Ogawa E, Tateno F, Uchiyama T, Yamamoto T, Yamanishi T.
Parkinsons Dis. 2011;2011:924605. doi: 10.4061/2011/924605.
0
0
0
Mitochondrial contribution to Parkinson's disease pathogenesis.
Schapira AH, Gegg M.
Parkinsons Dis. 2011;2011:159160. doi: 10.4061/2011/159160.
0
0
0
Brief cognitive tests in the screening of dementia in Parkinson's disease.
Pagonabarraga J, Kulisevsky J.
Mov Disord. 2011 Aug 1;26(9):1764; author reply 1764-5. doi: 10.1002/mds.23801. No abstract available.
0
0
0
Comentarios
En ningún caso la información facilitada constituye asesoramiento por parte de Zambon
Con el aval de:
En colaboración con:
